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Abstract
Purpose
To analyse nocturnal intraocular pressure (IOP) fluctuations in patients with obstructive
sleep apnea syndrome (OSAS) using a contact lens sensor (CLS) and to identify associa-
tions between the OSAS parameters determined by polysomnographic study (PSG) and
IOP changes.
Method
Prospective, observational study. Twenty participants suspected of having OSAS were
recruited. During PSG study, IOP was monitored using a CLS placed in the eye of the
patient. The patients were classified according to the apnea-hypopnea index (AHI) in two
categories, severe (>30) or mild/moderate (<30) OSAS. We evaluated several parameters
determined by the IOP curves, including nocturnal elevations (acrophase) and plateau
times in acrophase (PTs) defined by mathematical and visual methods.
Results
The IOP curves exhibited a nocturnal acrophase followed by PTs of varying extents at
which the IOP remained higher than daytime measurement with small variations. We found
significant differences in the length of the PTs in patients with severe OSAS compared to
those with mild/moderate disease (P = 0.032/P = 0.028). We found a positive correlation
between PTs and OSAS severity measured by the total number of apneic events (r = 0.681/
0.751 P = 0.004/0.001) and AHI (r = 0.674/0.710, P = 0.004/0.002). Respiratory-related
arousal and oxygen saturation also were associated significantly with the IOP PT length.
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Conclusions
Periods of nocturnal IOP elevation lasted longer in severe OSAS patients than those with
mild/moderate OSAS and correlate with the severity of the disease. The length of the noctur-
nal PT is also associated to respiratory parameters altered in patients with OSAS.
Introduction
Obstructive sleep apnea syndrome (OSAS) is a breathing disorder with a high prevalence. It is
characterized by repeated episodes of upper airway collapse during sleep that cause sympa-
thetic stimulation, hypertension, awakenings, hypoxia and hypercapnia in the patients. Chron-
ically untreated OSAS is considered a risk factor for other diseases such as systemic
hypertension, heart alterations, neurovascular diseases and type II diabetes [1–4]. An over-
night sleep study polysomnography (PSG) is required for definitive diagnosis of OSAS. The
disease severity can be classified based on the apnea-hypopnea index (AHI) as severe >30,
moderate (15–30), mild (5–14.9)and normal <5[2].
Glaucoma is an optic neuropathy characterized by the progressive degeneration of retinal
ganglion cells eventually causing blindness. Glaucoma affects around sixty million and is the
second most common cause of loss of sight worldwide [5]. Approximately 2.4% of population
older than 40 years have glaucoma; this percentage increases to 7% in those older than 70 years
[5,6]. For this reason, the prevalence of glaucoma is projected to be higher with the population
growth and ageing [7]. Several studies have established a relation between OSAS and glau-
coma, the increased prevalence of glaucoma in patients with OSAS and the significant associa-
tion between glaucoma and the OSAS severity have been reported [8–13]. Likewise, a higher
prevalence of OSAS has been found in patients with glaucoma [14,15]. However, whether
OSAS is a risk factor in glaucoma onset or progression is still under current debate.
Among the risk factors implicated in progression of glaucoma, the intraocular pressure
(IOP) is currently the only controllable factor [16,17] and to reduce high IOP is the unique tar-
get of the available treatments [18,19]. Several groups have found a relation between IOP
changes over long periods of time and deterioration of the visual fields (VFs) found in glau-
coma patients [20–22]. IOP variations also occur during short time periods. Daily IOP values
follow a circadian rhythm; several authors have reported a nocturnal increase of IOP values
[23–27]. Some studies have indicated that this IOP elevation might be greater in patients with
glaucoma compared to healthy controls [28,29]. Moreover changes in the bodily and/or head
positions are associated with IOP variations; thus, the IOP increases with movement from
standing and sitting to a supine position, and with neck movements outside the neutral posi-
tion [30–32]. Additionally, ocular movements, blinking, or sleep phases can induce IOP fluctu-
ations [33]. How these IOP fluctuations can contribute to the onset and progression of
glaucoma is not completely understood. It is believed that the IOP increase could directly dam-
age the optic nerve but also this elevation could affect the blood flow indirectly harming the
optic nerve [34–36]. Finally, it has been described that astrocytes in the optic nerve head are
mechanosensitive and can respond to the mechanical stress induced by IOP increase, reducing
the trophic support or changes in extracellular remodeling in the optic nerve [37,38]. The asso-
ciation between an elevated IOP, as principal risk factor of glaucoma, and the presence of
OSAS is still unclear.
A hindrance to establish the role of IOP fluctuations in the onset and/or progression of
glaucoma has been the lack of a continuous IOP monitoring system. Clinicians obtain most
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IOP measurements during the day while the patient is sitting and the neck is in the neutral
position, a practice that can underestimate the actual IOP. To ensure more reliable IOP stud-
ies, Sensimed AG (Lausanne, Switzerland) developed a contact lens sensor (CLS) that allows
24-hour semi-continuous monitoring to detect IOP variations and peaks throughout the day.
The device is a soft silicon contact lens designed to stay on the corneal surface for up to 24
hours. The CLS has a micro-sensor that measures circumferential changes in the corneoscleral
area. Leonardi et al. reported that these variations were correlated significantly with the IOP
fluctuations[39]. The measurements or “bursts” are the median of these 30-second periods
measured every 5 minutes, and they are considered a data point on the IOP graphs.
The purpose of the current study was to determine the changes in the IOP during sleep in
patients who underwent PSG to diagnosis OSAS. We evaluated the correlation between the
OSAS severity and several IOP-associated parameters in the study patients.
Methods
Participants
Twenty Caucasian participants (16 men, 4 women; mean age, 53.60 ± 10.35 years) were
included in this prospective study. They were selected among patients subjected to polisomno-
graphic study (PSG) in the Sleep Disorders Unit, at the Department of Neurophysiology, Clı´n-
ica Universidad de Navarra. We selected patients with a high suspicion of OSAS based on their
medical records, they received the details of the study and provided written informed consent
for study inclusion. The presence of OSAS, determined by PSG, was confirmed in all patients
except for patients 3 and 17 who had an apnea-hypopnea index <5. The patients were older
than 18 years with non-ocular diseases except for ocular hypertension in the case of patients 7
and 14.
They were classified based on the AHI as having mild <15, moderate 15–30, or severe >30
OSAS. The exclusion criteria were previous corneal surgeries, corneal abnormalities (scars,
leucomas ectasias), a previous diagnose of glaucoma, and severe dry eye (Schirmer test <5
mm). In order to discard the previous presence of glaucoma, we reviewed the medical histories
of the patients, some of them followed in our department. Table 1 shows the anthropometric
data of the patients and the prescribed medication during the study.
We measured the initial IOP in both eyes by pneumotonometry (Table 1) and placed the
CLS in the eye of the patients between 4 and 6 pm the evening before the start of PSG. The
right eye was chosen to place the CLS in all patients except patient 11 who was placed in the
left eye. The following day between 9 and 10 am the CLS was removed from the eye using con-
junctival forceps under topical anesthesia and the data obtained were analyzed. During wake
periods, the patients received artificial tears to minimize discomfort. The ethics committee of
Navarra approved the study protocol, which was conducted in accordance with the Declara-
tion of Helsinki.
Instrumentation
The Sensimed Triggerfish contact lens (Sensimed AG) detects changes in the ocular circumfer-
ence and corneal curvature at the corneoscleral junction that is associated with IOP fluctua-
tions (Fig 1).
The changes in ocular volume are detected by a strain gauge. After being placed in the eye
of a patient, the CLS measures 300 continuous events for 30 seconds every 5 minutes that cor-
respond to a “burst”. The values obtained were received by an antenna placed around the
patient eye and transmitted to a portable recorder by a cable. The acquired data stored in the
recorder was transferred to the computer for analysis. We obtained the raw data containing
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every value detected by the CLS and the median value for every set of measures (burst) that we
used in the study to create the IOP curves.
Polysomnographic study (PSG)
All patients underwent baseline PSG to confirm the clinical suspicion of OSAS. Nocturnal
sleep was recorded with Harmonie 5.2 (Stellate, Montreal, Canada) using Lamont 32-Sleep
amplifiers (Lamont Medical, Wisconsin, USA) as the regular sleep studies in our Unit. Fre-
quency of digitization was 200 Hz. The recording included EEG, tibial and chin electromyog-
raphy, electrooculography, oronasal flow, respiratory effort, oximetry, heart rate, and body
position. An electrocardiogram was recorded with two derivations (V3 and V5) that were
amplified band-pass filtered (0.30–30 Hz) and digitized at 500 Hz. The sleep stage classification
was performed according to the current American Academy of Sleep Medicine (AASM) crite-
ria[40]. The AASM score criteria also were used to establish the hypopneic and apneic events
and arousals. The parameters obtained from PSG are described in Table 2.
Table 1. Patient demographic data and medical records.
Patient Age
(yrs)
Gender Weight
(kg)
Height
(cm)
Body
mass
index
Sistolic/ Diastolic
Blood pressure
(mmHg)
Diseases (Cause
OSAS screening)
Medication Initial
IOP
R/L
1 55 Male 97 178 30.6 130/84 Suspected OSAS Omeprazole/Diclofenac 10/12
2 46 Male 84 186 24.3 114/74 Nasal Septum
Deviation
None 14/13
3 46 Female 62 170 21.3 100/63 Insomnia /Headache Trazodone/Lormetazepam 15/14
4 40 Male 102 186 29.5 110/70 Headache Ibuprofen PRN 14/18
5 67 Male 96 183 28.7 140/86 Hypertensive
Cardiopathy
Lisinopril/ Lercanidipine/ Doxazosin/
Esomeprazole
17/17
6 64 Male 91 173 26.9 146/86 Headache Omeprazole/Losartan/Bisoprolol/ Acetylsalicylic
acid/ Rosuvastatin/ Escitalopram
15/17
7 47 Male 98 Unkn Unkn Unkn Suspected OSAS Brimonidine/Timolol (ocular) 22/21
8 53 Male 84 184 24.8 145/94 Headache Ibuprofen PRN 20/17
9 42 Male 102 184 30.2 135/100 Arterial
Hypertension
Olmesartan/Amlodipine /Hydrochlorothiazide 21/20
10 44 Female 89 162 33.9 100/70 Asthenia Hydrocortisone/Fludrocortisone/
Desmopressin/ Acetylsalicylic acid/
Atorvastatin/ Pantoprazole
12/13
11 51 Male 96 176 31.0 125/75 Asthenia Pravastatin/Iron supplement, Pantoprazole,
Diclofenac
18/15
12 65 Male 80 172 27.0 119/81 Headache None 18/14
14 41 Male Unkn Unkn Unkn Unkn Suspected OSAS Latanoprost (ocular) 17/17
15 56 Female 99 170 34.3 120/70 Arterial
Hypertension
Enalapril/Atorvastatin 17/18
16 56 Male 90 166 32.7 170/100 Nasal Septum
Deviation
Enalapril 14/14
17 37 Female Unkn Unkn Unkn 106/71 Insomnia /Headache Duloxetine/ Tramadol/Acetaminophen/
Pantoprazole/Amitriptyline/Iron/ Diazepam
9/9
18 73 Male Unkn Unkn Unkn 100/65 Headache Unkn 13/16
19 61 Male 82 164 30.4 Unkn Headache Metformin, Tepazepam 12/13
20 50 Male 114 190 31.6 110/70 Arterial
Hypertension/
Snoring
Candesartan 8/7
21 65 Male 78 165 28.7 121/73 Arterial
Hypertension
Perindopril/ Indapamide 15/13
https://doi.org/10.1371/journal.pone.0229856.t001
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Sensimed Triggerfish data analysis
We analyzed the IOP fluctuations during the apneic-hypoapneic events, normal breathing
periods during sleep as well as awakening times in patient 1–12. To do that, we determined the
beginning and end of each event using the raw data and the median of every period was
obtained.
We evaluated several parameters associated with the IOP graphs obtained during PSG. We
calculated the wake/sleep slope, determined by linear regression based on the IOP measure-
ments obtained 1 hour before sleep and those obtained 1 hour after sleep onset; in the same
manner, we calculated the sleep/wake slope with the IOP values 1 hour before and 1 hour after
the awakening. We also determined the extent of the IOP acrophase defined by the measure-
ment of time in which the IOP increases, starting when the patient rests in bed and ends when
the IOP reaches the maximum elevation. The IOP acrophase was followed by a variable plateau
time (PT) during which the IOP showed small variations.
The plateau was measured according to two strategies. Using the first strategy (plateau A),
three doctors examined the graphs to reach a consensus on a PT duration. The second strategy
(plateau B) followed a signal processing approach based on measuring the median value on
moving windows of varying widths and use of Matlab software (Matlab and Statistics
Toolbox Release 2017b, The MathWorks, Inc., Natick, MA) to automatically detect the PT of
the IOP. The algorithm is first explained and illustrated below on synthetic data and thereafter
used for the 20 study patients. The algorithmic sensibility and its statistical justification will be
published elsewhere (Bragard et al. Automatic detection of plateaus in ocular physiological
data, manuscript in preparation). We provide a summary of the technique here. A variable
width and moving window covers part of the signal. The information of the signal covered by
a specific window is reported in two-dimensional graphs (Fig 2A–2D).
The two axes of these graphs correspond to the beginning time (Y-axis) and the end time
(X-axis) of the corresponding covering window, respectively. This technique is inspired and
has been previously described in a study of neuromotor control[41]. From the data enclosed in
the windows (see caption of Fig 2), we report the slope of a linear interpolation shown in Fig
Fig 1. Sensimed Triggerfish system. A. Sensimed Triggerfish is a soft silicon contact lens sensor (CLS) that contains
two strain gauges able to detect changes in the corneal shape. The lens has embedded a microprocessor and the
antenna. B. CLS transmits strain gauge data to an adhesive antenna that sends information to a recorder. The CLS
selected based on the curvature of the cornea is placed in the eye of the patient. The adhesive antenna is attached to the
area around the eye and connected through a cable to the portable recorder that is carried by the patient.
https://doi.org/10.1371/journal.pone.0229856.g001
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2B and the coefficient of determination (R^2) for the corresponding linear interpolation (dis-
played in Fig 2C). We also report the median value of the data enclosed in the window as
shown in Fig 2D. We worked directly on Fig 2D to identify the plateau time (PT) and Fig 2B
and 2C were used for the acrophase determination. From the observation of Fig 2D we identify
the presence of a plateau with a square rotated by 45 degrees with respect to the (X-Y) axes.
Fig 2. Method for the determination of the duration of the IOP plateau B. The time series of the IOP (insert A) is
transformed into two-dimensional plots (inserts B-D). In insert A, an example window beginning at time 00:00 and ending at
time 03:00 is drawn with a blue dashed line. The data enclosed in the window are used for evaluating inserts B-D. In B, the slope
of the linear regression of the window’s data is reported as a color code plot (in log scale). In C, the corresponding R^2
coefficient is reported. In insert D, the median value corresponding to the window is reported. In order to construct inserts B-D
all beginning, and end times are considered for defining the covering windows. In insert D, the plateau localization is extracted
as a square pattern with a 45-degree orientation with respect to the axes. The values corresponding to the example window
shown in insert A is reported by small marked squares in insert B-D for illustrative purpose. In insert 2E the approximate yellow
square upper right corner is a binarized picture of Fig 1D obtained by fixing a threshold value. The threshold value is associated
with the data distribution percentile. The case shown here corresponds to the 80th percentile. The rotated green square
(template) is chosen to have the same area as the yellow square and is translated around to seek for the optimum cross-
correlation between the template and the binarized pictured. An associated norm (between 0 and 1) gives the level of correlation
(here for the 80th percentile, we get a correlation of 0.891) and the best location for the superposition of the template and signal.
https://doi.org/10.1371/journal.pone.0229856.g002
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The basis and difficulty of the method lies in the setting of a threshold value to determine the
boundary of the square in Fig 2D. The threshold value transforms Fig 2D into a binary figure
(black and white, 0 and 1 only) as shown in the upper right part of Fig 2E.
The next step of the method consists in searching for the best match of the resulting binar-
ized object with an ideal template, i.e., a square with the same area (see Fig 2E, lower left cor-
ner) that is rotated by 45 degrees with respect to the axes. The built-in function that searches
for the best match optimization is directly available in the Matlab software and is called with
the function name “normxcorr2”. At this stage, because the choice for the threshold value for
the binarization of the pattern is arbitrary, we scan all possible percentiles from the data as pos-
sible percentiles. We report the best correlation between the binary object and the square tem-
plate pattern as a function of the percentile values as shown in Fig 3 (indicated by the black
circles).
For this illustrative synthetic case we know where the plateau starts and ends and therefore
we can evaluate the error as the sum of the difference in absolute values between the estimated
and real time of the beginning and end of the plateau (shown in Fig 3 by the green curve).
However, for all the patients considered here we need to calculate the beginning and end of
the plateau, therefore we need a measure that is comparable to the error. Here we have chosen
as a measure of the error the norm L2 defined as follows:
L2 ¼
1
Np
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
XNp
i¼1
ðyi   medianðyÞÞ
2
v
u
u
t
where Np is the number of points in the detected plateau, and median(y) is the median value
Fig 3. Different indicators used for the determination of the PT B. The circle symbols indicate the optimum cross-
correlation between template and signal at different values of the percentile (cut-off values). The dotted line indicates
the 0.95 level for reference purpose. The blue curve represents the corresponding PT duration (in minutes and rescaled
by 0.001 to fit in the vertical scale) extracted from our method at the different percentiles. The green curve represents
the error of the PT determination (see text Material and Methods for definition). The error is vanishing for percentiles
70th and 71st indicating that the method gives a perfect PT determination for such percentile values. The red curve
(with square symbols) is a L2 norm (see text Material and Methods for definition) that is expected to be minimum for
the percentile corresponding to the plateau detection.
https://doi.org/10.1371/journal.pone.0229856.g003
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for the detected plateau. Indeed, we observe that the norm L2 is minimum when the plateau is
detected. As a further check we ensure that when the plateau is detected, the correlation given
by “normxcorr2” is above the 95% cross-correlation that is taken as an additional cut-off value.
The plateau duration provided by the two strategies, plateaus A and B, are compared in the
Results section.
Statistical analysis
The Shapiro-Wilk test was used to determine if the samples deviated significantly from normal
distribution. Thus, differences between the severe and non-severe groups were analyzed by the
Student t-test for parametric data; the Mann-Whitney U-test was applied to the non-paramet-
ric parameters. To find associations between the parametric variables, we determined Pear-
son’s correlation coefficient for normal distributions or Spearman’s correlation coefficient in
non-parametric variables. The statistical study was performed using SPSS software version
20.0.1 (SPSS Inc., Chicago, IL).
Results
Subjects
Twenty patients who met the inclusion criteria underwent PSG (Table 1). Among the 20
patients, eleven had severe OSAS, five moderate OSAS, and four mild or no OSAS according
to the OSAS classification (Table 1). We divided the patients in two groups based on the
apnea-hypopnea index, severe group (AHI>15) and non-severe group (AHI<15). There were
no significant differences between groups in age, height, weight, body mass index, or blood
pressure (P> 0.05) (Table 3). We also reviewed the medical histories and concomitant medi-
cation use of the patients (Table 1).
The CLS was well tolerated generally; only patient 18 decided to have the sensor removed
before the end of the study. For this reason, we excluded this patient for the IOP study. Four-
teen patients had intense or mild conjunctival hyperemia that resolved in less than 24 hours.
Study of continuous IOP in patients with OSAS
IOP pressure was measured before sensor placement for each patient (Table 1). IOP values
were considered in a normal range in all patients. Only patient 7 showed an IOP of 22 mmHg,
slightly elevated. The patient had been previously diagnosed with high IOP and treated for this
reason with topical medication.
Table 3. Comparison of physical parameters between severe and non-severe patient groups.
Non-severe Severe
Mean ± SD Mean ± SD P value
Age 49.3 ± 9.5 55.9 ± 10.3 0.16
Weight 87 ± 13.3 93.5 ± 10.9 0.284
Height 172.5 ± 8.7 178 ± 9 0.239
Systolic Blood Pressure 121.7 ± 20.4 123.9 ± 19.7 0.828
Diastolic Blood Pressure 79.1 ± 14.1 77.8 ± 10.2 0.822
Body Mass Index 28.8 ± 4.8 29.3 ± 2.6 0.785
p value
� p<0.05
�� p � 0.01.
https://doi.org/10.1371/journal.pone.0229856.t003
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The analysis of the IOP fluctuations obtained by the sensor showed significant nocturnal
IOP increases (IOP acrophase), while patients were in bed compared to daytime, which con-
firmed previous observations [23,24]. (Fig 4).
Patients 15, 16, and 20 did not have IOPs with significant nocturnal acrophase. These
patients had great fluctuations in the measurements, while the median IOP values remained
similar during the study (Fig 4). We measured the IOP acrophase when the patient was lying
in bed and the wake-to-sleep and sleep-to-wake slopes (Table 4).
After the acrophase, the IOP peaks remained fairly constant for a varying extent that differ
depending on each patient and we refer to it as the plateau time (PT). We determined the PT
in every patient except patients 15, 16 and 20 (Table 4). In most patients, it remained stable
until the patient awakened and arose from bed (Fig 4). We followed two different approaches,
the first, PT A, was direct visual examination of the plateau magnitude by three different
observers. The second, PT B, was obtained through the previously described mathematical
approach (Table 4). Both methods showed a high level of correlation (r = 0.821, P<0.001)
(Table 5).
Relation of IOP and OSAS severity
We evaluated the correlation between the apneic episodes and IOP fluctuations in the first 12
patients with different degrees of OSAS. We did not obtain significant differences in the IOP
comparing non apnea vs apnea episodes. Moreover, we did not find specific IOP fluctuations
or peaks associated with the apneic episodes compared to post-apneic normal sleep breathing
or waking hours.
Fig 4. Spectrograms of signal profiles obtained from the CLS Sensimed Triggerfish in the 20 study eyes. Patient 18 opted to remove the
CLS before the end of the PSG. Red lines show the length of plateau A and the blue lines display the extent of plateau B. � Patients 15,16 and
20 do not show a IOP plateau. ��Patient 18 opted to remove the CLS before the end of the PSG.
https://doi.org/10.1371/journal.pone.0229856.g004
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Then, we focused on the curve created by the CLS signal and analyzed different parameters,
wake-to-sleep slope, acrophase duration, PT, and sleep-to-wake slope. We found significant
differences in PT when we categorized the patients as having severe and non-severe disease.
The comparison shows the longer plateaus times in the patients with severe disease compared
to those with non-severe disease (P = 0.032 and P = 0.028) (Fig 5).
PT B showed a positive association with the wake to sleep slope (r = 0.506, P = 0.046)
(Table 5).
We also evaluated associations between the parameters obtained with the PSG data that
defined OSAS degree (Table 2) and the values we have determined in the IOP curve (Table 4).
The PT A and PT B correlated positively with the OSAS severity determined by the AHI and
the total number of apneic events (Table 5). Moreover, we found a positive relation between
the plateaus and the number of arousals due to respiratory events (r = 0.548/ 0.540, P = 0.028/
0.031) (Table 5). The plateau time is negatively associated with the oxygen saturation meaning
that patients who have better oxygen saturation show shorter plateaus. In this sense, if we ana-
lyze the amount of time that patients remain with a saturation below 90%, this is associated
positively with the plateau length (r = 0.499/0.538, P = 0.049/0.032) (Table 5).
The PT A was correlated positively with the N2 sleep phase (r = 0.626, P = 0.009) and nega-
tively with the REM sleep periods (r = -0.589, P = 0.016).
We did not find any association between the initial IOP measured before the study and the
parameters of the curve. Moreover, there were not statistical difference between the initial IOP
in severe and non-severe patients (P = 0.652)
In summary, we found that PTs during sleep were associated with apneic severity in OSAS
patients. The results suggested that an increased number of arousals related to respiratory
causes and a lower oxygen saturation also are related to a longer PT.
Table 4. Evaluation of curve parameters obtained by the CLS during PSG.
Patient OSAS
Severity
Acrophase
(min)
Wake to Sleep
Slope
Sleep to wake
Slope
Plateau A
(min)
Plateau B
(min)
1 Severe 65 1.51 -1.12 345 410
2 Severe 195 1.61 -1.9 170 185
3 Non- Severe 115 0.35 -0.73 0 125
4 Severe 120 0.03 -0.44 0 110
5 Severe 185 0.21 n.d. 180 240
6 Non- Severe 152 1.11 -2.09 100 120
7 Severe 260 1.08 -1.09 354 425
8 Non- Severe 225 1.02 -0.57 140 115
9 Non -Severe 504 0.92 -1.36 30 90
10 Non -Severe 125 0.67 -0.35 0 45
11 Severe 55 1.94 -0.54 225 570
12 Severe 205 0.62 -0.85 15 105
14 Non-Severe 340 1.07 0.71 100 170
15 Non -Severe n.d. n.d. n.d. n.d. n.d.
16 Severe n.d. n.d. n.d. n.d. n.d.
17 Non-Severe 565 0.71 -1.07 110 125
18 Severe n.d. n.d. n.d. n.d. n.d.
19 Non-Severe 335 1.24 -0.88 86 250
20 Severe n.d. n.d. n.d. n.d. n.d.
21 Severe 430 0.07 -0.14 230 300
https://doi.org/10.1371/journal.pone.0229856.t004
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Discussion
We used a contact lens sensor (CLS) to determine IOP changes during sleep, including pre
and post sleep periods. The IOP changes have been determined by mvEq units measured every
5 minutes since the CLS was placed in the eye until it was removed. The data collected using
this system resembled a real situation, because the IOP was measured while the patient
remained asleep and undisturbed. The CLS was considered safe in the current study and the
patients tolerated the CLS well, with only one patient discontinuing the study and deciding to
remove the lens referring a foreign-body sensation. Fourteen patients had transient conjuncti-
val hyperemia that resolved 24 hours after lens removal. These adverse events occurred fre-
quently but were mild and they have been reported previously [42–44].
We measured the IOP fluctuations once for each study patient. Repeated measurements are
always desirable to establish the system reliability; however, several studies have already
reported very good reproducibility with the Sensimed CLS for IOP measurements, for exam-
ple, Mansouri et al. reported the high duplicability of the system by performing two measure-
ments with the CLS in the same patients 6 to 8 days apart[45]. Due to the nature of the current
study that was associated with PSG we obtained only one recording per patient.
Several groups have tried to answer questions related to accuracy and validity of the CLS
IOP values by comparing the data obtained from the CLS with traditional IOP measurements
obtained either from the fellow eye or from the same study eye before or after placement of the
CLS. Mansouri et al. also reported a highly significant correlation between both measurements
using the IOP in the fellow eye for comparison,[42] and Aptel et al. also reported this
Table 5. Analysis of the correlation between the IOP curve obtained values and the PSG parameters.
Arousal
respiratory
events
Non-
respiratory
arousals
index
Time
saturation
lower of 90%
Total
number
apnea-
hypopnea
Apnea-
Hypopnea
Index
Plateau
A
Plateau
B
Wake
to sleep
slope
Sleep to
Wake
Slope
% N1
Sleep
Phase
% N2
Sleep
Phase
% N3
Sleep
Phase
% REM
Phase
PlateauA r 0.548� 0.120 0.499� 0.681�� 0.674�� 0.821�� 0.426 -0.119 -0.069 0.626�� -0.353 -0.589�
p 0.028 0.658 0.049 0.004 0.004 <0.001 0.100 0.673 0.798 0.009 0.180 0.016
PlateauB r 0.540� -0.116 0.538� 0.751�� 0.710�� 0.821�� 0.506� 0.045 -0.154 0.460 -0.304 -0.310
p 0.031 0.669 0.032 0.001 0.002 <0.001 0.046 0.873 0.570 0.073 0.253 0.243
r correlation coefficient, p p value
� p<0.05
�� p � 0.01. Spearman/Pearson correlation test
https://doi.org/10.1371/journal.pone.0229856.t005
Fig 5. Comparison of measured plateaus in patients with Severe or Non-Severe OSAS. The duration of the Plateaus
obtained by the two methods A and B was significantly longer in the severe OSAS patients compare to those with a
mild/moderate disease.
https://doi.org/10.1371/journal.pone.0229856.g005
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association[46]. Other studies, however, have reported a lower correlation between both values
[47,48].
As we described previously, literature have established an association between the presence
of OSAS and glaucoma, however, only a few studies have attempted to evaluate the IOP fluctu-
ations in patients with OSAS. Thus, Huseyinoglu et al. found small differences in the IOP
depending on the OSAS severity; however, the authors failed to find a correlation between the
AHI and IOP [49]. The literature has provided contradictory results, with some studies report-
ing a positive correlation between the AHI and IOP,[11,50–52] while others did not [53]. Each
of these studies obtained a few IOP measurements during the ocular examination. The first
study that evaluated continuously the IOP in patients with OSAS and used SENSIMED trig-
gerfish as a IOP sensor was done by Shinmei and collaborators. They have examined the
impact of apnea-hypopnea events and IOP values in seven patients, reporting a significant
decrease in the IOP associated to apnea-hypopnea events in four out of seven patients [54].
Interestingly these fluctuations have no impact in the global IOP curves [54], showed a similar
pattern to those obtained in our study (Fig 5).
We performed a similar analysis evaluating the IOP fluctuations during the apneic episodes
versus non apneic periods in the first 12 patients with different degrees of OSAS. We did not
find significant differences in the IOP comparing non apnea vs apnea episodes. We have
focused on the analysis of the IOP curves in the OSAS patients, most of the curves showed a
pattern. We observed an IOP elevation starting when the individual lies on the bed. The IOP
reaches a plateau (PT) that usually finish when the patient wakes up and leave the bed with a
decrease in the IOP that creates a negative slope. We found that patients with severe OSAS had
significantly longer PTs compared to those with moderate or mild OSAS. We also found an
association between the PT duration and the apneic severity evaluated by the AHI and the
total number of apneic and hypopneic events (Table 5). We observed that patients with severe
OSAS tends to reach the plateau in the early hours during bedtime and the IOP was main-
tained at that high level during longer periods. In this sense, we found a statistically significant
association between the slope of the acrophase and the duration of the plateau (Table 5). Being
high IOP a risk factor for glaucoma disease, severe OSAS could contribute among other factors
to glaucoma onset and be more prevalent in these patients.
Several studies using the CLS have established the presence of a nocturnal acrophase in a
great number of individuals; some studies have suggested that this acrophase is more frequent
in patients with glaucoma (80% to 90%) than healthy subjects (70%)[29]. Results also have sug-
gested that enlargement of this peak happens more frequently in patients with glaucoma com-
pared to healthy subjects [29]. The nocturnal acrophase and subsequent plateau could
contribute to disease onset and progression.
The PT also was correlated with other respiratory parameters related to OSAS such as the
arousal related to the respiratory events or the duration of severe hypoxic conditions. Recur-
rent hypoxia besides vascular alterations described before that might affect the optic nerve,
activates the renin-angiotensin system (RAS)[55], causing an increase in the choroidal blood
flow that can ultimate lead to an increase in elevated episcleral venues pressure [56]. The ocu-
lar RAS has been also implicated in formation of aqueous humor, the drainage of which modu-
lates IOP [57–60]. Therefore, several researchers have shown that RAS inhibition with
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type I receptors blockers is
beneficial in both normotensive and glaucomatous eyes [61–63]. Moreover, the IOP has
decreased in patients treated orally with ACE inhibitors (captopril) or AT-1 receptor blockers
(losartan) [64,65]. These data suggested that RAS activation could partly explain the IOP
increase in patients with OSAS.
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Patients 15, 16, and 20 had greater IOP fluctuations over time and not an overall change in
contrast to the nocturnal acrophase widely described in the other patients (Fig 5). Analysis of
the specific characteristics of these patients showed the commonalities: the age range and the
presence of arterial hypertension treated with an antihypertensive drug in monotherapy. Two
patients were treated with enalapril, an ACE inhibitor, and the third with candesartan, an AT1
receptor antagonist. The treatment might have been related to the “abnormal” IOP pattern
observed by the mechanism described above. Others also were treated with these drugs but in
combination with other antihypertensive agents. These patients had at least partially the noc-
turnal acrophase and plateaus (Fig 5). We cannot explain these phenomena; further studies
should confirm these preliminary observations that associate these treatments and IOP
fluctuations.
The current study had some limitations, with the first related to the population characteris-
tics and the small sample size. The number was small compared to other studies using the
same system; the reason could be that patients with OSAS are less aware of the risk of uncon-
trolled high IOP than patients with glaucoma, more responsive to wearing a CLS. Another lim-
itation was due to the CLS properties; IOP variations were measured in mvEq, which cannot
be converted to mmHg, the conventional pressure unit. Extrapolating the obtained data to
conventional IOP values is a limitation. A contact lens can modify the corneal shape and thick-
ness, which might have affected the values obtained. In this sense some authors have pointing
out that the measures obtained by the CLS after several hours can be affected by these changes
losing accuracy[66]. Finally, the CLS signal can be noisy and these large fluctuations should be
analyzed in a subsequent study; in the current study the fluctuations due to bodily positions
were minimized due to PSG. Most patients were supine during the monitoring except for
patient 6 who alternated between supine and lateral positioning. Despite these limitations, this
study can contribute to understand better la relationship between OSAS and glaucoma.
In conclusion, the Sensimed Triggerfish allowed evaluation of the IOP fluctuations in
patients with different OSAS severities. The results indicated that patients with OSAS might
have normal IOP measurements during medical visits but their IOPs might be elevated sub-
stantially at night, the phenomenon has been also described for the general population. In this
study we have observed that IOP increase remains elevated, creating a plateau, which lengths
are significantly longer in patients with severe OSAS based on the AHI and total number of
apneic/hypopneic events. We also found an association between high IOP and low oxygen sat-
uration, both parameters that have been related to glaucoma progression.
Further prospective studies are needed to demonstrate that the length of the nocturnal IOP
elevations in patients with OSAS has a role in glaucoma onset and/or progression.
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